AU2001247474A1 - Compounds for the treatment of psychiatric or substance abuse disorders - Google Patents
Compounds for the treatment of psychiatric or substance abuse disordersInfo
- Publication number
- AU2001247474A1 AU2001247474A1 AU2001247474A AU4747401A AU2001247474A1 AU 2001247474 A1 AU2001247474 A1 AU 2001247474A1 AU 2001247474 A AU2001247474 A AU 2001247474A AU 4747401 A AU4747401 A AU 4747401A AU 2001247474 A1 AU2001247474 A1 AU 2001247474A1
- Authority
- AU
- Australia
- Prior art keywords
- psychiatric
- compounds
- treatment
- substance abuse
- abuse disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 201000009032 substance abuse Diseases 0.000 title 1
- 231100000736 substance abuse Toxicity 0.000 title 1
- 208000011117 substance-related disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18981100P | 2000-03-16 | 2000-03-16 | |
US18972800P | 2000-03-16 | 2000-03-16 | |
US18972700P | 2000-03-16 | 2000-03-16 | |
US60189811 | 2000-03-16 | ||
US60189727 | 2000-03-16 | ||
US60189728 | 2000-03-16 | ||
PCT/US2001/008398 WO2001068104A1 (en) | 2000-03-16 | 2001-03-15 | Compounds for the treatment of psychiatric or substance abuse disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001247474A1 true AU2001247474A1 (en) | 2001-09-24 |
Family
ID=27392624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001247474A Abandoned AU2001247474A1 (en) | 2000-03-16 | 2001-03-15 | Compounds for the treatment of psychiatric or substance abuse disorders |
Country Status (5)
Country | Link |
---|---|
US (3) | US8030294B2 (en) |
EP (1) | EP1274444B1 (en) |
AU (1) | AU2001247474A1 (en) |
ES (1) | ES2425114T3 (en) |
WO (1) | WO2001068104A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2425114T3 (en) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-choline and uridine for the treatment of alcohol abuse |
ES2170649B1 (en) * | 2000-03-29 | 2003-06-16 | Ferrer Int | USE OF CDP-HILL IN THE TREATMENT OF ALCOHOLIC ABSTINENCE. |
EA006654B1 (en) * | 2001-01-16 | 2006-02-24 | Женсет С. А. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
US20020103429A1 (en) * | 2001-01-30 | 2002-08-01 | Decharms R. Christopher | Methods for physiological monitoring, training, exercise and regulation |
US20050283053A1 (en) * | 2002-01-30 | 2005-12-22 | Decharms Richard C | Methods for physiological monitoring, training, exercise and regulation |
US6996261B2 (en) * | 2001-01-30 | 2006-02-07 | Decharms R Christopher | Methods for physiological monitoring, training, exercise and regulation |
WO2003092796A1 (en) * | 2002-05-03 | 2003-11-13 | Musc Foundation For Research Development | Method, apparatus and system for determining effects and optimizing parameters of vagus nerve stimulation |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
AU2003238872A1 (en) * | 2002-06-04 | 2003-12-19 | Avicena Group, Inc. | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
US20040092809A1 (en) * | 2002-07-26 | 2004-05-13 | Neurion Inc. | Methods for measurement and analysis of brain activity |
UA83011C2 (en) * | 2002-11-08 | 2008-06-10 | Зе Маклин Хоспитал Корпорейшн | Compounds for treating tobacco dependence and withdrawal syndrome |
JP4717444B2 (en) * | 2002-12-20 | 2011-07-06 | ザ マクレーン ホスピタル コーポレーション | Compounds for normalization of sleep / wake cycles |
US7524515B2 (en) * | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
CA2522708C (en) | 2003-04-29 | 2013-05-28 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
WO2004100899A2 (en) * | 2003-05-13 | 2004-11-25 | The Mclean Hospital Corporation | Use of secretin in treatments of disorders associated with the amygdala |
WO2004109300A2 (en) * | 2003-06-03 | 2004-12-16 | Decharms R Christopher | Methods for magnetic resonance signal perturbations measurement |
EP1727554A4 (en) * | 2003-10-08 | 2009-09-30 | Mclean Hospital Corp | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
WO2005034874A2 (en) * | 2003-10-08 | 2005-04-21 | The Mclean Hospital Corporation | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
KR20060128995A (en) * | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
EP1765075A4 (en) * | 2004-06-10 | 2010-11-10 | Mclean Hospital Corp | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
WO2005123097A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder |
EP1784199A4 (en) * | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
WO2006039416A2 (en) * | 2004-10-01 | 2006-04-13 | The Mclean Hospital Corporation | Cns assay for prediction of therapeutic efficacy for neuropathic pain and other functional illnesses |
JP2008520280A (en) * | 2004-11-15 | 2008-06-19 | デチャームス,クリストファー | Application of nerve tissue stimulation using light |
CN101370488B (en) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | Compositions for increasing insulin sensitivity |
EP1951308B1 (en) * | 2005-11-25 | 2013-02-20 | Gisela Susilo | Combination preparations containing physiological cell membrane constituents including phosphatidylserine, choline and a pyrimidine nucleoside/nucleotide |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
JP2010508997A (en) * | 2006-11-09 | 2010-03-25 | オレキシジェン・セラピューティクス・インコーポレーテッド | Methods for administering weight loss drugs |
TWI504419B (en) | 2006-11-09 | 2015-10-21 | Orexigen Therapeutics Inc | Layered pharmaceutical formulations |
WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US20100041620A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods for improving frontal brain bioenergetic metabolism |
US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
RU2616496C2 (en) * | 2010-01-11 | 2017-04-17 | Ориксиджен Терапьютикс, Инк. | Methods of weight loss therapy in patients with dominant depression (versions) |
WO2011143534A1 (en) * | 2010-05-13 | 2011-11-17 | The Mclean Hospital Corporation | Methods for the treatment of psychiatric disorders |
WO2012048243A2 (en) * | 2010-10-08 | 2012-04-12 | University Of Utah Research Foundation | Depression disorder therapeutics with creatine analogs |
AU2012311293B2 (en) | 2011-09-19 | 2014-02-20 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
RU2495670C2 (en) * | 2011-12-30 | 2013-10-20 | Андрей Владимирович Михайлов | Method for addictive behaviour correction |
DK2858640T3 (en) | 2012-06-06 | 2020-06-29 | Nalpropion Pharmaceuticals Llc | Composition for use in a method of treating obesity and obesity in patients with high cardiovascular risk |
WO2014014960A1 (en) * | 2012-07-16 | 2014-01-23 | Dignity Health | Treating of epilepsy and alcohol addiction with creatine |
WO2015120299A1 (en) | 2014-02-07 | 2015-08-13 | University Of Utah Research Foundation | Combination of creatine, an omega-3 fatty acid, and citicoline |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3873698A (en) | 1973-10-10 | 1975-03-25 | Addiction Research And Treatme | Method of combatting morphine addiction and toxification |
US4048316A (en) * | 1974-03-04 | 1977-09-13 | Penn Nathar W | Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning |
US4115576A (en) * | 1974-04-02 | 1978-09-19 | Penn Nathar W | Compositions and method of employing the same for inhibiting alcohol intoxication |
US4027017A (en) * | 1974-07-16 | 1977-05-31 | Chugai Seiyaku Kabushiki Kaisha | Method of treating alcoholism |
US4346084A (en) | 1980-02-29 | 1982-08-24 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering lithium and choline |
US4569929A (en) | 1980-02-29 | 1986-02-11 | Massachusetts Institute Of Technology | Cytidyl diphosphocholine-drug composition |
IT1207106B (en) | 1980-04-18 | 1989-05-17 | Made Italiana Srl Ora Searle I | PHARMACEUTICAL PREPARATION CONTAINING CITIDIN DISFOFOCOLINA ABSORBABLE ORALLY |
EP0263533A3 (en) | 1983-03-01 | 1990-05-30 | C.R.C. Compagnia di Ricerca Chimica S.p.A. | A method for preparing the cytidine monophosphate of 5-acetamido-3,5-dideoxy-d-glycero-d-galactononulosaminic acid |
DE3400276A1 (en) | 1984-01-05 | 1985-07-18 | Ferrer Internacional S.A., Barcelona | Use of CDP-choline for the treatment of neurological disturbances |
ATE43348T1 (en) * | 1985-01-24 | 1989-06-15 | Neopharmed Spa | ACYLATED CYTIDIN DIPHOSPHATE CHOLINES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
IT1200589B (en) | 1985-02-14 | 1989-01-27 | Gibipharma Spa | NATURAL DERIVATIVES PHARMAGOLOGICAL ACTIVITY |
IT1201474B (en) | 1985-10-01 | 1989-02-02 | Vincenzo Zappia | MACROMOLECULARIZED DERIVATIVES OF CDP-COLINA, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
JPS63208524A (en) | 1987-02-25 | 1988-08-30 | Nippon Oil & Fats Co Ltd | Sleep rhythm improver |
JPH0828589B2 (en) | 1987-02-25 | 1996-03-21 | 日本電気株式会社 | LSI cooling structure |
AU2789989A (en) | 1987-10-28 | 1989-05-23 | Pro-Neuron, Inc. | Acylated uridine and cytidine and uses thereof |
US5691320A (en) * | 1987-10-28 | 1997-11-25 | Pro-Neuron, Inc. | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis |
IT1219667B (en) | 1988-06-21 | 1990-05-24 | Polifarma Spa | USE OF URIDINE IN THE PHARMACOLOGICAL TREATMENT OF DISORDERS DUE TO ALTERATED DOPAMINERGIC BALANCE |
US4999382A (en) | 1988-10-26 | 1991-03-12 | Massachusetts Institute Of Technology | Compositions for treating tobacco withdrawal symptoms and methods for their use |
US5179126A (en) | 1988-10-26 | 1993-01-12 | Massachusettes Institute Of Technology | Compositions for treating tobacco withdrawl symtoms and methods for their use |
RU2003332C1 (en) * | 1989-06-09 | 1993-11-30 | Борис Витальевич Страдомский | Agent for treatment depression |
US5069895A (en) * | 1989-11-09 | 1991-12-03 | Diamond Ivan F | Methods for the treatment of alcohol intoxication and dependence |
US5635486A (en) | 1990-05-11 | 1997-06-03 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Ophthalmic composition comprising a sleep adjusting substance |
JPH0418034A (en) | 1990-05-11 | 1992-01-22 | Kanegafuchi Chem Ind Co Ltd | Eye drop composition |
DK0588917T3 (en) | 1991-05-29 | 2001-02-12 | Abbott Lab | Isoxazole and isothiazole compounds that enhance cognitive function |
GB9200293D0 (en) | 1992-01-08 | 1992-02-26 | Wyeth John & Brother Ltd | Piperazine derivatives |
US5278176A (en) | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
GB9303157D0 (en) | 1993-02-17 | 1993-03-31 | Scotia Holdings Plc | Treatment of a group of related disorders |
JPH0710823A (en) | 1993-06-22 | 1995-01-13 | Teijin Ltd | N-3 unsaturated fatty acid derivative and pharmaceutical composition containing the derivative |
JP2500372B2 (en) | 1993-11-10 | 1996-05-29 | 科学技術庁航空宇宙技術研究所長 | Tensile impact test equipment |
US5472958A (en) | 1994-08-29 | 1995-12-05 | Abbott Laboratories | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function |
ATE332127T1 (en) | 1994-11-08 | 2006-07-15 | Avicena Group Inc | USE OF CREATINE OR CREATINENOLOGIST TO TREAT HUNTINGTON CHOREA, PARKINSON'S DISEASE AND AMYOTROPHIC LATERAL SCLERosis |
JPH08183737A (en) * | 1994-12-28 | 1996-07-16 | Advance Co Ltd | Alcohol absorption inhibitor |
US5691365A (en) | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
AU4231897A (en) * | 1996-08-16 | 1998-03-06 | Southwest Foundation For Biomedical Research | Compositions and methods for delivery of nucleic acids to hepatocytes |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
PT956013E (en) | 1996-10-11 | 2003-08-29 | Scarista Ltd | PHARMACEUTICAL PREPARATION COMPOSING Eicosapentaenoic acid and / or stearidonic acid |
GB9623859D0 (en) | 1996-11-15 | 1997-01-08 | Chiroscience Ltd | Novel compounds |
US6852870B2 (en) | 1999-03-22 | 2005-02-08 | Andrew Stoll | Omega-3 fatty acids in the treatment of depression |
US5958896A (en) | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
US6153653A (en) | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
US5977174A (en) | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
CA2313024C (en) | 1997-12-10 | 2008-06-03 | Severson, Mary L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
US20060128671A1 (en) | 1998-04-02 | 2006-06-15 | The General Hospital Corporation | Compositions containing a combination of a creatine compound and a second agent |
US6132724A (en) | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
EP1140104B1 (en) | 1998-07-31 | 2007-09-26 | Massachusetts Institute of Technology | Treatment of alzheimer's disease by increasing cytidine levels in vivo |
US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
HN1999000146A (en) | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE, ADHD AND MICROADENOMAS. |
US6696495B2 (en) | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
DE19929995B4 (en) | 1999-06-30 | 2004-06-03 | Skw Trostberg Ag | Use of creatine and / or creatine derivatives for the treatment of mental disorders in women |
AU8028600A (en) | 1999-10-20 | 2001-04-30 | Eliezer Rapaport | Methods, pharmaceutical and therapeutic compositions for administering adenosine |
US6258794B1 (en) | 1999-12-14 | 2001-07-10 | The Mclean Hospital Corporation | Treatment of mental conditions including depression |
ES2425114T3 (en) | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-choline and uridine for the treatment of alcohol abuse |
ES2170649B1 (en) | 2000-03-29 | 2003-06-16 | Ferrer Int | USE OF CDP-HILL IN THE TREATMENT OF ALCOHOLIC ABSTINENCE. |
US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
US6520921B1 (en) | 2000-06-20 | 2003-02-18 | Eastman Kodak Company | Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication |
US6727231B1 (en) | 2000-10-12 | 2004-04-27 | Repligen Corporation | Uridine therapy for patients with elevated purine levels |
IL139224A (en) | 2000-10-23 | 2009-09-01 | David Rutenberg | Anti depressant, stress suppressor and mood improver |
AU2002220211A1 (en) | 2000-12-07 | 2002-06-18 | Mclean Hospital Corporation | Use of magnetic resonance imaging in diagnosis of membrane fluidity-related disorders |
US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
EP1390378B1 (en) | 2001-04-30 | 2009-06-17 | Trommsdorff GmbH & Co. KG Arzneimittel | Pharmaceutically active uridine esters |
US6541043B2 (en) | 2001-08-28 | 2003-04-01 | Dexgen Pharmaceuticals, Inc. | Method and synergistic composition for treating attention deficit/hyperactivity disorder |
WO2003032914A2 (en) | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
US20030114415A1 (en) | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
WO2003066004A2 (en) | 2002-02-08 | 2003-08-14 | President And Fellows Of Harvard College | Therapeutic compounds |
AU2003241281A1 (en) | 2002-03-27 | 2003-10-13 | The Regents Of The University Of California | Synergy of dopamine d2 and adenosine a2 receptors activates pka signaling via beta/gamma dimers |
US20030224435A1 (en) | 2002-05-16 | 2003-12-04 | Scott Seiwert | Detection of abused substances and their metabolites using nucleic acid sensor molecules |
US7026301B2 (en) | 2002-10-17 | 2006-04-11 | New York University | Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil |
UA83011C2 (en) | 2002-11-08 | 2008-06-10 | Зе Маклин Хоспитал Корпорейшн | Compounds for treating tobacco dependence and withdrawal syndrome |
JP4717444B2 (en) | 2002-12-20 | 2011-07-06 | ザ マクレーン ホスピタル コーポレーション | Compounds for normalization of sleep / wake cycles |
US20040266659A1 (en) | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
WO2005034874A2 (en) | 2003-10-08 | 2005-04-21 | The Mclean Hospital Corporation | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
EP1727554A4 (en) | 2003-10-08 | 2009-09-30 | Mclean Hospital Corp | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
WO2005123097A1 (en) | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder |
EP1765075A4 (en) | 2004-06-10 | 2010-11-10 | Mclean Hospital Corp | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
EP1784199A4 (en) | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
US20100041621A1 (en) | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
US20100041620A1 (en) | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods for improving frontal brain bioenergetic metabolism |
WO2011143534A1 (en) * | 2010-05-13 | 2011-11-17 | The Mclean Hospital Corporation | Methods for the treatment of psychiatric disorders |
-
2001
- 2001-03-15 ES ES01920418T patent/ES2425114T3/en not_active Expired - Lifetime
- 2001-03-15 EP EP01920418.9A patent/EP1274444B1/en not_active Expired - Lifetime
- 2001-03-15 AU AU2001247474A patent/AU2001247474A1/en not_active Abandoned
- 2001-03-15 US US09/810,109 patent/US8030294B2/en active Active
- 2001-03-15 WO PCT/US2001/008398 patent/WO2001068104A1/en active Application Filing
-
2003
- 2003-05-01 US US10/427,306 patent/US7863254B2/en not_active Expired - Fee Related
-
2008
- 2008-01-18 US US12/016,874 patent/US8575219B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8575219B2 (en) | 2013-11-05 |
WO2001068104A1 (en) | 2001-09-20 |
EP1274444B1 (en) | 2013-05-15 |
US20030220291A1 (en) | 2003-11-27 |
EP1274444A4 (en) | 2006-06-14 |
US20080132472A1 (en) | 2008-06-05 |
US7863254B2 (en) | 2011-01-04 |
US20020019364A1 (en) | 2002-02-14 |
EP1274444A1 (en) | 2003-01-15 |
ES2425114T3 (en) | 2013-10-11 |
US8030294B2 (en) | 2011-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001247474A1 (en) | Compounds for the treatment of psychiatric or substance abuse disorders | |
AU2935200A (en) | Compounds for the treatment of obesity | |
IL209842A0 (en) | Compounds for the treatment of metabolic disorders | |
MXPA03007960A (en) | Compounds and methods for the treatment of urogenital disorders. | |
IL153425A0 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders | |
AU2001292480A1 (en) | Novel pyridazine compounds for the treatment of diabetes | |
AU2001272852A1 (en) | Composition for the treatment of migraine | |
AU2000276362A1 (en) | Composition for the treatment of diabetes | |
AU2002334870B8 (en) | Combinations for the treatment of immunoinflammatory disorders | |
IL151890A0 (en) | Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
AU6910600A (en) | Methods for the treatment of mental disorders | |
AU2000258650A1 (en) | 2-piperidone compounds for the treatment of cancer | |
AU5038299A (en) | Process for the biocidal treatment of surfaces | |
HK1051692A1 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain. | |
AU2001293891A1 (en) | New combination for the treatment of asthma | |
EP1461030A4 (en) | Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma | |
IL154378A0 (en) | Compounds for the treatment of addictive disorders | |
CZ20011872A3 (en) | Isonipecotamides for the treatment of integrin-mediated disorders | |
AU2002258798A1 (en) | Methods for the treatment of hepatic disorders | |
SI1468686T1 (en) | S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders | |
AU2000272704A1 (en) | Use of compounds for the treatment of obesity | |
AU4475300A (en) | Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression | |
AU2002327697A1 (en) | Compounds for the treatment of pain | |
AU2002351665A1 (en) | Agents for treating lesions of the nervous system | |
AU2002218338A1 (en) | Treatment of psychiatric disorders with trimethyl-bicyclo(2.2.1)heptane derivatives |